Company
Santhera is a Swiss specialty pharmaceutical company focusing on the discovery, development and marketing of small molecule products for the treatment of severe neuromuscular diseases, an area of high unmet medical needs.
Clinical Trials
Santhera is currently recruiting patients for clinical studies in
- Friedreich’s Ataxia in US and Europe
- Leber’s Hereditary Optic Neuropathy in Germany and in UK
- Dyskinesia in Parkinson’s Disease in US
Development Programs
Santhera has three compounds in five clinical programs: SNT-MC17 in Friedreich’s Ataxia, Duchenne Muscular Dystrophy and Leber’s Hereditary Optic Neuropathy, JP-1730 in Dyskinesia in Parkinson’s, and SNT-317 in Congenital Muscular Dystrophy.
Latest News
April 21, 2008
Santhera Shareholders Approve all Board Proposals at Annual Shareholders' Meeting
February 29, 2008
Santhera Reports Financial Results and Significant Operational Progress for 2007
